Holen Sie sich die Stockscreener-App
1.11
0.89%
-0.01
Handel nachbörslich:
1.12
0.01
+0.90%
Schlusskurs vom Vortag:
$1.12
Offen:
$1.1302
24-Stunden-Volumen:
42,869
Relative Volume:
0.35
Marktkapitalisierung:
$24.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-58.20M
KGV:
-0.4264
EPS:
-2.603
Netto-Cashflow:
$-47.21M
1W Leistung:
-1.77%
1M Leistung:
-1.77%
6M Leistung:
-3.48%
1J Leistung:
-31.48%
1-Tages-Spanne:
$1.10
$1.14
1-Wochen-Bereich:
$1.10
$1.175
52-Wochen-Spanne:
$0.9612
$1.78
Boundless Bio Inc Stock (BOLD) Company Profile
Firmenname
Boundless Bio Inc
Sektor
Branche
Telefon
(858) 766-9912
Adresse
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.11 | 25.07M | 0 | -58.20M | -47.21M | -2.603 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-22 | Eingeleitet | Guggenheim | Buy |
| 2024-04-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-22 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Boundless Bio Inc Aktie (BOLD) Neueste Nachrichten
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
Bold Biosciences 2025 10-K: ecDNA-Enabled Cancer Drug Development, Spyglass Platform & BBI-940 Kinesin Degrader Overview - Minichart
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Bitget
Boundless Bio beats fourth quarter loss estimates By Investing.com - Investing.com Canada
Boundless Bio 10-K: $0 Revenue, $(58.2)M Net Loss, $(63.6)M Operating Loss - TradingView
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewswire Inc.
Exit Recap: Is Boundless Bio Inc stock a smart retirement pickEarnings Summary Report & AI Enhanced Trading Signals - baoquankhu1.vn
Breakouts Watch: Can MSPRI sustain its profitabilityMarket Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Boundless Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Rezolute to Participate in the Citizens Life Sciences Conference - Bitget
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight – Company AnnouncementFT.com - Financial Times
BOLD Should I Buy - Intellectia AI
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Signal Recap: How liquid is AMBIWS stock2025 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Volume Recap: Can Broadstone Net Lease Inc outperform under higher oil prices2025 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Nextech exits Boundless Bio (NASDAQ: BOLD) with reported 0% ownership - Stock Titan
Will Boundless Bio Inc. stock continue dividend increasesInflation Watch & Consistent Income Trade Recommendations - mfd.ru
What Makes CTS (CTS) a New Buy Stock - Bitget
What Makes KB Financial (KB) a Strong Momentum Stock: Buy Now? - Bitget
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why - Yahoo Finance
Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial - TipRanks
FMR LLC Reduces Stake in Boundless Bio Inc: A Strategic Portfoli - GuruFocus
What is the long term forecast for Boundless Bio Inc. stockJuly 2025 Analyst Calls & Weekly High Conviction Ideas - mfd.ru
Investment Recap: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARJuly 2025 Chart Watch & Fast Exit Strategy with Risk Control - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Fed Watch: Does Boundless Bio Inc have pricing powerWall Street Watch & Momentum Based Trading Signals - baoquankhu1.vn
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Fund Flows: Can Boundless Bio Inc weather a recession2025 Investor Takeaways & AI Forecast Swing Trade Picks - baoquankhu1.vn
Boundless Bio CEO Zachary Hornby to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Cancer biotech Boundless Bio preps Guggenheim fireside chat with online webcast - Stock Titan
Is Boundless Bio (NASDAQ:BOLD) In A Good Position To Invest In Growth? - simplywall.st
Patterns Watch: Is Boundless Bio Inc subject to activist investor interestQuarterly Trade Review & Risk Managed Investment Strategies - baoquankhu1.vn
We're Keeping An Eye On Boundless Bio's (NASDAQ:BOLD) Cash Burn Rate - Yahoo Finance
Layoff Tracker: Gilead Continues California Cuts With 34 Laid Off - BioSpace
Is Boundless Bio Inc. stock a good pick for beginnersJuly 2025 Short Interest & AI Driven Price Predictions - mfd.ru
Boundless Bio (BOLD) awards 140,000-share stock option to finance chief - Stock Titan
Day Trade: How does HSIC compare to its peers2025 Key Lessons & Capital Efficiency Focused Ideas - baoquankhu1.vn
Update Report: Is Alamos Gold Inc forming bullish engulfing patterns2025 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Short Squeeze: Is Toppoint Holdings Inc a speculative investmentJuly 2025 WrapUp & Consistent Profit Trade Alerts - baoquankhu1.vn
Aug Drivers: Can MBNKP continue delivering strong returnsWeekly Trade Analysis & Smart Investment Allocation Insights - baoquankhu1.vn
VIX Spike: Is PHVS forming a bullish divergenceJuly 2025 Weekly Recap & Technical Pattern Based Signals - baoquankhu1.vn
Boundless Bio’s kinesin degrader gains IND approval - BioWorld MedTech
FDA accepts Boundless Bio’s IND for novel cancer drug BBI-940 - Investing.com Canada
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 And Extends Cash Runway - TradingView
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway - marketscreener.com
Boundless Bio halts trial to back new breast cancer drug to 2028 - Stock Titan
Can Boundless Bio Inc. stock withstand economic slowdownMarket Activity Recap & AI Driven Price Predictions - bollywoodhelpline.com
What is POLA’s market positionRecession Risk & Daily Technical Forecast Reports - bollywoodhelpline.com
Finanzdaten der Boundless Bio Inc-Aktie (BOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):